[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chiang Mai University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":221},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,55,88,117,143,169,195],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100638753","phase-4-maternal-immunization-with-tetanus-toxoid-reduced-diphtheria-toxoid-reduced-dose-2-g-recombinant-pertussis-vaccine-tdap2gen-and-its-effect-on-the-immune-response-in-thai-infants-up-to-15-18-months-old-100638753",false,"NCT07621341","Maternal Immunization With Tetanus Toxoid, Reduced Diphtheria Toxoid, Reduced-dose (2 µg) Recombinant Pertussis Vaccine (TdaP2gen) and Its Effect on the Immune Response in Thai Infants up to 15-18 Months Old","Maternal Immunization With Tetanus Toxoid, Reduced Diphtheria Toxoid, Reduced-dose (2 µg) Recombinant Pertussis Vaccine (TdaP2gen) and Its Effect on the Immune Response to Tetanus, Diphtheria and Pertussis in Thai Infants up to 15-18 Months Old: An Open-label, Randomized Controlled Trial","M-PRIME","Phase 1: Pregnant women\n\nInclusion Criteria:\n\n* Pregnant women aged 20 to 45 years\n* Healthy women in good general health\n* Gestational age between 20 and 32 weeks at enrollment\n* Singleton pregnancy\n* Low-risk, uncomplicated pregnancy as assessed by an obstetrician\n* No evidence of congenital anomalies identified on prenatal ultrasonographic screening\n* Willing to receive TdaP2gen vaccination and comply with collection of biological specimens as specified in the study protocol\n* Willing to allow their infant to receive either whole-cell pertussis-containing or acellular pertussis-containing combination vaccines according to the study randomization process, and to allow collection of biological specimens from the infant as specified in the study protocol\n* Able and willing to provide written informed consent prior to study participation\n\nExclusion Criteria:\n\n* Receipt of a tetanus-, diphtheria-, and chemical-detoxified pertussis-containing vaccine within 1 year prior to enrollment, or receipt of a tetanus-, diphtheria-, and genetic-detoxified pertussis-containing vaccine (TdaPgen) or genetic-detoxified acellular pertussis vaccine (aPgen) within 2 years prior to enrollment, including during the current pregnancy\n* History of laboratory-confirmed or clinically diagnosed pertussis infection within 1 year prior to enrollment\n* Presence of underlying medical conditions that may affect study outcomes, including but not limited to malignancy, autoimmune disease, immunodeficiency, epilepsy, hypertension, renal disease, or liver disease, as determined by the investigators\n* Pregnancy complications including hypertension (blood pressure \\>140\u002F90 mmHg with proteinuria, or \\>150\u002F100 mmHg regardless of proteinuria), current antihypertensive treatment, or preeclampsia\n* Endocrine disorders including hyperthyroidism, untreated hypothyroidism, or impaired glucose tolerance (e.g., type 1 or type 2 diabetes mellitus) diagnosed before or during pregnancy requiring treatment beyond dietary control\n* Severe or progressive neurological disorders, including epilepsy or a history of Guillain-Barré syndrome\n* Receipt of immunosuppressive agents, immunomodulatory agents, or high-dose systemic corticosteroids (\\>2 mg\u002Fkg\u002Fday, \\>20 mg\u002Fday, or equivalent) for more than 14 consecutive days within 6 months prior to enrollment\n* History of stillbirth, neonatal death, or recurrent spontaneous abortion (≥3 episodes).\n* Current medical or surgical treatment for prevention of preterm labor during the current pregnancy\n* Receipt of blood products, blood components, or immunoglobulins within 6 months prior to enrollment\n* Receipt of live attenuated vaccines within 3 months or any other vaccines within 28 days prior to enrollment\n* History of hypersensitivity or adverse reactions to study vaccines or vaccine components, or history of severe allergic reactions such as anaphylaxis to any vaccine\n* Behavioral, cognitive, or psychiatric conditions that, in the opinion of the investigator, may interfere with study participation or protocol compliance\n* History of smoking, alcohol abuse, or intravenous drug use that, in the opinion of the investigator, may interfere with study assessments or outcomes\n* Fever (body temperature ≥38.0°C or equivalent) within 72 hours prior to enrollment\n* Acute illness within 4 weeks prior to enrollment\n* Contraindications to intramuscular vaccination, including thrombocytopenia, coagulation disorders, hemophilia A or B, or use of anticoagulant therapy during pregnancy\n* Concurrent participation in another clinical study involving investigational vaccines or medications during participation in this study\n* Any medical or obstetric condition that, in the opinion of the study investigator, may interfere with study assessments or increase the risk to the mother or infant associated with study participation\n\nPhase 2: Infants\n\nInclusion Criteria:\n\n\\- All infants born to pregnant women enrolled in Phase 1 who received TdaP2gen vaccination during pregnancy will be eligible for enrollment to Phase 2 study\n\nExclusion Criteria:\n\n* Gestational age \\\u003C32 weeks (very preterm birth)\n* Birth weight \\\u003C1,500 grams (very low birth weight)\n* Presence of major congenital anomalies identified after birth, including congenital abnormalities associated with genetic disorders, congenital infections, or severe structural abnormalities involving major organ systems such as the central nervous system, cardiovascular system, respiratory system, hepatobiliary and gastrointestinal system, or genitourinary system\n* Presence of severe neonatal medical conditions that may affect immune responses to study vaccines, including but not limited to severe respiratory distress, severe bronchopulmonary dysplasia, hypoxic ischemic encephalopathy (HIE), severe intraventricular hemorrhage (IVH), severe sepsis, non-physiologic jaundice, neonatal autoimmune thrombocytopenia, neurological disorders such as neonatal convulsions, necrotizing enterocolitis, or intracranial hemorrhage\n* Presence of conditions associated with increased risk of serious adverse reactions to study vaccines\n* Any medical condition or circumstance that, in the opinion of the study investigator, may interfere with study assessments or increase the risk to the participant associated with study participation",true,"ALL","0 Days","45 Years",{"count":22,"type":23},320,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","Pertussis remains a major global public health problem. In Thailand, pertussis vaccination is recommended during pregnancy at 20-32 weeks' gestation, together with routine childhood diphtheria-tetanus-pertussis vaccination administered as a primary series at 2, 4, and 6 months and booster doses at 18 months and 4-6 years of age.\n\nTdaP2gen, a newly developed combined tetanus, diphtheria, and recombinant genetically detoxified acellular pertussis vaccine containing 2 µg pertussis antigen, has shown favorable safety and non-inferior immunogenicity compared with existing pertussis vaccines. However, data on its use in pregnant women, transplacental antibody transfer, and potential immune interference in infants remain limited.\n\nThis study aims to evaluate the safety and immunogenicity of TdaP2gen in pregnant women, assess antibody transfer to newborns, and investigate immune responses to tetanus, diphtheria, and pertussis following primary and booster pertussis-containing vaccinations in infants and toddlers, including comparisons between whole-cell and acellular pertussis-containing vaccine schedules.",[29,30,31,32],"Pertussis","Diphtheria","Tetanus","Vaccine-Preventable Diseases",[34,35,36,37,38,39,40,41],"Safety","Immunogenicity","Immune interference","Pregnant women","Newborns","Infants and young children","Pertussis-containing vaccine","Genetically-detoxified recombinant acellular pertussis vaccine","NOT_YET_RECRUITING","2026-05-27",{"date":45,"type":46},"2026-06-02","ACTUAL",{"date":48,"type":23},"2026-05-26",{"date":50,"type":23},"2030-12-31",{"name":52,"class":53},"Chiang Mai University","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":18,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":24,"phases":67,"briefSummary":69,"conditions":70,"keywords":75,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":54},"100640623","rectus-sheath-block-versus-transversus-abdominis-plane-block-for-analgesia-in-laparoscopic-bariatric-surgery-100640623","NCT07592091","Rectus Sheath Block Versus Transversus Abdominis Plane Block for Analgesia in Laparoscopic Bariatric Surgery","Comparison of Rectus Sheath Block and Transversus Abdominis Plane Block for Analgesia in Laparoscopic Bariatric Surgery: A Randomized Controlled Trial","RSB-TAPB","Inclusion Criteria:\n\n* Patients aged 20-60 years old\n* Scheduled for elective LBS including laparoscopic sleeve gastrectomy, proximal jejunal bypass, and Roux-en-Y gastric bypass\n* American Society of Anesthesia (ASA) physical status III\n* Have ability to communicate and understand the study and accept to participate in the study\n\nExclusion Criteria:\n\n* Patients who have following underlying disease: severe hepatic impairment \\[diagnosed of cirrhosis (Child-Pugh C)\\], coagulopathy (diagnosed of disease associated with abnormal coagulation), pre-existing neurological deficits, chronic pain (diagnosed of chronic pain disease or current use regular analgesic drugs), or any drug addiction.\n* Known allergy to bupivacaine or weighing less than 60 kg, as the planned doses of bupivacaine may exceed safe maximum limits.\n* Patient with previous foregut surgery including esophageal, gastric, liver and pancreases resection.","20 Years","60 Years",{"count":66,"type":23},96,[68],"NA","This randomized controlled trial aims to compare the analgesic efficacy of rectus sheath block (RSB) and transversus abdominis plane block (TAPB) in patients undergoing laparoscopic bariatric surgery. Both techniques are regional anesthesia methods used as part of multimodal analgesia to reduce postoperative pain and opioid requirements.\n\nEligible participants will be randomly assigned to receive either a RSB or a TAPB after general anesthesia. Postoperative pain scores, opioid consumption, recovery outcomes, area of sensory loss, time to first rescue analgesia, and block-related adverse events will be assessed and compared between the two groups.\n\nThis study will help determine which regional anesthesia technique provides more effective postoperative analgesia for laparoscopic bariatric surgery",[71,72,73,74],"Rectus Sheath Block","Transverse Abdominis Plane Block","Opioid Consumption, Postoperative","Analgesia",[71,76,77,78,79],"Transversus abdominis plane block","Laparoscopic bariatric surgery","opioid consumption","analgesia","2026-05-13",{"date":82,"type":46},"2026-05-18",{"date":84,"type":23},"2026-05-10",{"date":86,"type":23},"2031-06-30",{"name":52,"class":53},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":18,"minAge":63,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":24,"phases":98,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":54},"100533759","phase-4-a-protocol-based-furosemide-stress-test-to-evaluate-renal-recovery-during-continuous-renal-replacement-therapy-100533759","NCT06229990","A Protocol Based-Furosemide Stress Test to Evaluate Renal Recovery During Continuous Renal Replacement Therapy","A Protocol Based-Furosemide Stress Test to Evaluate Renal Recovery During Continuous Renal Replacement Therapy (FST-STOP): A Randomized Controlled Trial","FST-STOP","Inclusion Criteria:\n\n* Adult 20 year of age or older\n* Acute kidney injury (AKI) stage 3 according to Kidney Disease Improving Global Outcomes (KDIGO) classification with oliguria (urine \\\u003C400 ml\u002Fday)\n* Initiate CRRT in ICU (medical ICU, surgical ICU, cardiac care unit) for at least 48 hours (time for initiation and modality of CRRT can adjust by clinician)\n\nExclusion Criteria:\n\n* Use any inotropic drug (norepinephrine, epinephrine, dopamine, dobutamine)\n* Blood urea nitrogen (BUN) \\>80 mg\u002FdL\n* Serum K \\\u003C3.5 or \\>5 mmol\u002FL\n* Arterial potential of Hydrogen (pH) \\\u003C7.3\n* Serum bicarbonate (HCO3) \\\u003C15 mmol\u002FL\n* Urine volume \\\u003C400 or \\>2,100 mL\u002Fday\n* Urine creatinine clearance (CrCl) at 6 hours \\>20 mL\u002Fmin\n* Previous chronic kidney disease (CKD) stage 5 or estimated glomerular filtration rate (eGFR) \\\u003C15 mL\u002Fmin\u002F1.73 m2\n* Previous RRT within 14 days\n* Kidney transplantation\n* Obstructive etiology for AKI\n* Toxin\u002Fdrug that necessitates RRT\n* Allergy to furosemide\n* Moribund with expected death within 24 hours\n* Pregnancy",{"count":97,"type":23},80,[26],"Currently, continuous renal replacement therapy (CRRT) is the main modality for renal support in critically ill patients with hemodynamic instability. Most studies have investigated the timing of RRT initiation. However, prolonged CRRT demonstrated the association of many unexpected events, such as catheter-related complications, catheter-related blood stream infection, hypotension, hypothermia, tachycardia, and atrial fibrillation. Up to now, there is a lack of evidence regarding the timing of withholding CRRT. The furosemide stress test (FST) is a tool that is easy to use and has more availability. The investigators aimed to apply FST to evaluate renal recovery compared with standard treatment in critically ill patients undergoing CRRT.",[101],"Acute Kidney Injury",[103,104,105,106,107],"Acute kidney injury","Continuous renal replacement therapy","Furosemide stress test","Critical care","CRRT","RECRUITING","2026-03-20",{"date":111,"type":46},"2026-03-24",{"date":113,"type":46},"2024-01-01",{"date":115,"type":23},"2028-12-31",{"name":52,"class":53},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":18,"minAge":63,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":24,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100627240","telerehab-exerbrain-bridging-physical-and-cognitive-therapy-in-stroke-100627240","NCT07446062","Telerehab Exerbrain: Bridging Physical and Cognitive Therapy in Stroke","Effects of Web-Based Physical-Cognitive Telerehabilitation Exergaming on Physical and Cognitive Performance in Chronic Stroke Survivors: Protocol for a Randomized Controlled Trial","Inclusion Criteria:\n\n* diagnosed with ischemic or hemorrhagic stroke at least 6 months before enrollment\n* aged between 20 and 80 years\n* able to walk at least 10 meters with or without assistive devices\n* able to perform sit-to-stand safely with or without assistive devices\n* can see the screen of a tablet or notebook computer at a distance of at least 60 cm\n* have a stable medical condition and can follow study instructions\n* frequent users of a mobile phone, tablet, or notebook computers\n\nExclusion Criteria:\n\n* have medical conditions or complications that would be unsafe to exercise\n* have neglect, impaired communication, or uncorrected visual problems \\[30\\], or - have severe spasticity of the upper or lower extremities (Modified Ashworth Scale ≥ 3)","80 Years",{"count":126,"type":23},52,[68],"The goal of this clinical trial is to learn if a web-based exercise and cognitive training (physical-cognitive) program works to improve movements and brain function in adults with long-term stroke. It will also learn whether the program is safe and enjoyable.\n\nThe main questions it aims to answer are:\n\nDoes the program improve walking, balance, strength, and reduce fall risk? Does the program improve cognitive skills such as memory, attention, and problem-solving? Researchers will compare the online exercise-and-cognitive training program to usual care to see if the program leads to greater improvements.\n\nParticipants will:\n\n* Be randomly assigned to either the online training group or the usual care group\n* If in the training group, complete the home-based program for 12 weeks.\n* Take part in physical and cognitive tests before and after the program",[130,131,132,133,134],"Stroke","Tele-rehabilitation","Exercise","Motor Abilities","Cognitive Abilities","2026-02-25",{"date":137,"type":46},"2026-03-03",{"date":139,"type":23},"2026-02",{"date":141,"type":23},"2027-03",{"name":52,"class":53},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":18,"minAge":64,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":24,"phases":152,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":54},"100531571","low-intensity-physical-cognitive-exercise-and-cognitive-function-100531571","NCT06201533","Low-intensity Physical-cognitive Exercise and Cognitive Function","Effects of Low-intensity Exercise on Cognitive Function, Blood Biomarkers, and Metabolomic Alterations of Older Adults at Risk of Developing Dementia","Inclusion Criteria:\n\n* meeting the criteria for MCI (or mNCD) based on the recent DSM-V criteria\n* comprehend instructions and able to comply with the study procedures\n* not taking any medications for their cognition and not planning to start medications during the study trial\n\nExclusion Criteria:\n\n* presence of medical condition(s) unsafe to exercise or affect cognition and mobility\n* presence of depressive symptoms\n* exercise regularly",{"count":151,"type":23},64,[68],"This study aims to examine the effects of low-intensity, combined physical-cognitive exercise on cognitive function of older people with mild cognitive impairment (MCI) and identify the mechanisms by which this exercise protocol exerts cognitive function. Older adults with MCI will be recruited to either an exercise or a control group. Low-intensity, combined physical-cognitive exercise will be prescribed to the exercise group 3 times per week for 3 months while the control group will maintain their routine lifestyle. It is hypothesized that at the end of the trial, participants in the exercise group will demonstrate significant improvement in cognitive performance and circulating biomarkers compared to baseline and the control group.",[155],"Mild Cognitive Impairment",[157,158,159,160],"mild cognitive impairment","low intensity exercise","cognitive function","fibroblast growth factor 21","2026-02-18",{"date":163,"type":46},"2026-02-19",{"date":165,"type":46},"2024-04-07",{"date":167,"type":23},"2026-03",{"name":52,"class":53},{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":18,"minAge":63,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":179,"phases":4,"briefSummary":180,"conditions":181,"keywords":185,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":4},"100585644","preoperative-anemia-affected-to-postoperative-outcomes-in-liver-resection-100585644","NCT06905041","Preoperative Anemia Affected to Postoperative Outcomes in Liver Resection","The Impact of Preoperative Anemia on Postoperative Outcomes in Liver Resection: A Propensity Score Matching Analysis","Inclusion Criteria:\n\n* All genders, age 20 to 75 years old who undergoing elective liver resection\n* American Society of Anesthesiologists (ASA) physical status classification of I-III\n\nExclusion Criteria:\n\n* Living donor liver resection\n\nWithdrawal criteria:\n\n* Unresectable tumor\n* Cardiac arrest during operation","75 Years",{"count":178,"type":23},728,"OBSERVATIONAL","To assess the impact of preoperative anemia on postoperative outcomes in patients undergoing liver resection",[182,183,184],"Liver Resection","Anemia","Postoperative Mortality and Morbidity",[186],"Preoperative anemia, liver resection, posteoperative complication","2025-03-25",{"date":189,"type":46},"2025-04-01",{"date":191,"type":23},"2025-03-31",{"date":193,"type":23},"2027-01-31",{"name":52,"class":53},{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":18,"minAge":63,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":24,"phases":204,"briefSummary":205,"conditions":206,"keywords":208,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":54},"100559954","phase-4-colistin-monotherapy-vs-colsitin-fosfomycine-in-crab-infection-100559954","NCT06570850","Colistin Monotherapy vs Colsitin-fosfomycine in CRAB Infection","Efficacy of Colistin Monotherapy Versus Colistin Combined With Fosfomycin Against Carbapenem-Resistant Acinetobacter Baumannii Infections","Inclusion Criteria:\n\n* ≥ 20 years old patients who have CRAB infections (pneumonia, urinary tract infection, skin and soft tissue infection, bloodstream infection)\n* Able to provide informed consent or having a legal proxy who can provide informed consent in case the subject is unable to provide consent on his own\n\nExclusion Criteria:\n\n* Minimum inhibitory concentration (MIC) of colistin \\> 2 mg\u002FL\n* Complicated infection with inadequate source controlled\n* Intracranial infection\n* Infective endocarditis\n* Intraabdominal infection\n* Bone and joint infection\n* Allergic to or have contraindication(s) to any treatment regimen in the study\n* Polymicrobial infection with Carbapenem-resistant Psuedomonas aeruginosa, Carbapenem-resistant Enterobacterales (CRE), Vancomycin-resistant Enterococcus (VRE)\n* Pregnancy\n* Previous treatment with colistin or fosfomycin more than 96 hours\n* Life expectancy of 24 hour or less\n* Refusal to participate in the study\n* Hospice treatment",{"count":203,"type":23},188,[26],"The goal of this clinical trial is to evaluate the efficacy of colistin compared with colistin plus fosfomycin against carbapenem-resistant Acinetobacter baumanii infection in Thailand. The main questions it aims to answer the following main questions:\n\n1. Which group has better clinical response at end of treatment\n2. Which group has better clinical response at 72 hours and micrological cure at 72 hours and at end of treatment",[207],"Infection Due to Carbapenem Resistant Acinetobacter",[209,210,211,212],"carbapenem resistant Acinetobacter baumanni","CRAB","Colistin","Fosfomycin","2024-08-22",{"date":215,"type":46},"2024-08-26",{"date":217,"type":46},"2023-04-01",{"date":219,"type":23},"2025-07",{"name":52,"class":53},""]